185.20
Irhythm Technologies Inc stock is traded at $185.20, with a volume of 471.89K.
It is down -1.00% in the last 24 hours and up +5.59% over the past month.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
See More
Previous Close:
$187.30
Open:
$184.81
24h Volume:
471.89K
Relative Volume:
1.09
Market Cap:
$5.94B
Revenue:
$560.03M
Net Income/Loss:
$-150.66M
P/E Ratio:
-38.11
EPS:
-4.86
Net Cash Flow:
$-87.43M
1W Performance:
+1.49%
1M Performance:
+5.59%
6M Performance:
+41.42%
1Y Performance:
+147.11%
Irhythm Technologies Inc Stock (IRTC) Company Profile
Name
Irhythm Technologies Inc
Sector
Industry
Phone
415-632-5700
Address
699 8TH STREET, San Francisco, CA
Compare IRTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IRTC
Irhythm Technologies Inc
|
185.03 | 6.03B | 560.03M | -150.66M | -87.43M | -4.86 |
|
ABT
Abbott Laboratories
|
123.70 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.99 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
358.50 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
89.72 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.62 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Irhythm Technologies Inc Stock (IRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Initiated | Evercore ISI | In-line |
| Aug-20-25 | Initiated | BofA Securities | Buy |
| May-02-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-24 | Resumed | Wells Fargo | Equal Weight |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Jun-20-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-11-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Feb-07-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-22 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Feb-24-22 | Upgrade | Needham | Hold → Buy |
| Jan-18-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-12-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-11-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-21-21 | Resumed | Canaccord Genuity | Buy |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-02-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Colliers Securities | Buy → Neutral |
| Jan-29-21 | Reiterated | Needham | Hold |
| Nov-17-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-11-20 | Initiated | Needham | Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Aug-07-20 | Upgrade | Colliers Securities | Neutral → Buy |
| Aug-05-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-10-20 | Initiated | William Blair | Outperform |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Feb-20-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Sep-13-18 | Reiterated | Canaccord Genuity | Buy |
| Sep-06-18 | Initiated | Chardan Capital Markets | Buy |
| Aug-02-18 | Upgrade | Dougherty & Company | Sell → Neutral |
| Jul-16-18 | Downgrade | Dougherty & Company | Neutral → Sell |
| Dec-01-17 | Initiated | Dougherty & Company | Neutral |
View All
Irhythm Technologies Inc Stock (IRTC) Latest News
iRhythm Technologies Inc. stock trendline breakdownJuly 2025 Sector Moves & Fast Gain Stock Tips - newser.com
Is iRhythm Technologies Inc. (I25) stock a contrarian opportunityJuly 2025 Outlook & Daily Volume Surge Signals - newser.com
iRhythm Technologies Inc. stock prediction for this weekExit Point & AI Driven Stock Movement Reports - newser.com
Technical signs of recovery in iRhythm Technologies Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
iRhythm Technologies $IRTC Shares Sold by Oppenheimer Asset Management Inc. - MarketBeat
Research Analysts Issue Forecasts for IRTC Q1 Earnings - MarketBeat
Key metrics from iRhythm Technologies Inc.’s quarterly data2025 Market WrapUp & AI Based Buy and Sell Signals - newser.com
What margin trends mean for iRhythm Technologies Inc. stockJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Will iRhythm Technologies Inc. stock deliver long term returnsWeekly Gains Report & Precise Swing Trade Alerts - newser.com
US$220That's What Analysts Think iRhythm Technologies, Inc. (NASDAQ:IRTC) Is Worth After These Results - simplywall.st
Will iRhythm Technologies Inc. stock reach Wall Street targetsIndex Update & Weekly Top Stock Performers List - newser.com
Key resistance and support levels for iRhythm Technologies Inc.Weekly Trade Report & Weekly Hot Stock Watchlists - newser.com
Why The Narrative Around iRhythm Technologies Is Shifting Following Recent Analyst and Market Updates - Yahoo Finance
iRhythm Technologies (NASDAQ:IRTC) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
iRhythm Technologies (NASDAQ:IRTC) Price Target Raised to $242.00 at Citigroup - MarketBeat
iRhythm Technologies (IRTC): Premium Valuation as Losses Persist, Profitability Targeted Within 3 Years - Yahoo Finance
iRhythm Technologies (NASDAQ:IRTC) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
iRhythm Technologies (NASDAQ:IRTC) Price Target Raised to $240.00 - MarketBeat
iRhythm Technologies (NASDAQ:IRTC) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
iRhythm Technologies, Inc. (NASDAQ:IRTC) Q3 2025 Earnings Call Transcript - Insider Monkey
BTIG Research Forecasts Strong Price Appreciation for iRhythm Technologies (NASDAQ:IRTC) Stock - MarketBeat
Jennison Associates LLC Has $45.80 Million Stock Position in iRhythm Technologies $IRTC - MarketBeat
iRhythm Technologies stock price target raised to $212 from $193 at Canaccord - Investing.com Australia
Is iRhythm Technologies Inc. stock a safe buy before earningsTrade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
iRhythm Technologies Reports Strong Q3 2025 Growth - The Globe and Mail
JP Morgan Maintains iRhythm Technologies (IRTC) Overweight Recommendation - Nasdaq
Goldman Sachs Maintains iRhythm Technologies (IRTC) Neutral Recommendation - Nasdaq
iRhythm Technologies (NASDAQ:IRTC) Releases Quarterly Earnings Results - MarketBeat
IRhythm targets $735M–$740M 2025 revenue as free cash flow turns positive, driven by EHR integration and innovative channels - MSN
iRhythm Technologies Inc (IRTC) Stock Price, Trades & News - GuruFocus
IRTC Target Price Raised to $212 by Canaccord Genuity Today | IR - GuruFocus
iRhythm Enhances Executive Severance Policy Amid Growth - The Globe and Mail
Citigroup Raises iRhythm Technologies (IRTC) Price Target to $24 - GuruFocus
iRhythm Technologies Q3 2025 Earnings Preview - MSN
JP Morgan Raises Price Target on IRTC to $240, Maintains Overwei - GuruFocus
iRhythm Q3 2025 slides: record revenue and improving margins prompt outlook boost - Investing.com Australia
iRhythm Q3 2025 Results: Revenue Jumps 30.7%, Shares Hit 52-Week HighNews and Statistics - IndexBox
iRhythm Technologies, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:IRTC) 2025-10-31 - Seeking Alpha
Goldman Sachs Raises Price Target for iRhythm Technologies (IRTC) to $202 | IRTC Stock News - GuruFocus
iRhythm Technologies Inc buy JPMorgan Chase & Co. - sharewise.com
Why iRhythm (IRTC) Stock Is Trading Up Today - TradingView
IRTC Q3 Deep Dive: New Account Growth and AI Partnerships Fuel Guidance Raise - Yahoo Finance
iRhythm Technologies stock price target raised to $244 from $193 at Needham - Investing.com Canada
BTIG Maintains iRhythm Technologies (IRTC) Buy Recommendation - Nasdaq
Is iRhythm Technologies Inc. stock bottoming outWeekly Stock Report & Technical Analysis for Trade Confirmation - newser.com
Needham Raises iRhythm Technologies (IRTC) Price Target to $244 - GuruFocus
BTIG Raises iRhythm Technologies (IRTC) Price Target to $215 | I - GuruFocus
iRhythm Technologies stock price target raised to $215 from $195 at BTIG - Investing.com Canada
iRhythm submits Zio MCT to FDA, beats Street as analysts call Q3 performance ‘epic’ - MassDevice
IRhythm Technologies Q3 Adjusted Loss Narrows, Revenue Rises; Lifts 2025 Revenue Guidance - MarketScreener
Irhythm Technologies Inc Stock (IRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):